West Pharmaceutical Services (NYSE:WST – Get Free Report) updated its FY24 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $6.55 to $6.75 for the period, compared to the consensus estimate of $6.42. The company issued revenue guidance of $2.875 billion to $2.905 billion from $2.870 billion to $2.900, compared to the consensus revenue estimate of $2.87 billion. West Pharmaceutical Services also updated its FY 2024 guidance to 6.550-6.750 EPS.
West Pharmaceutical Services Trading Up 15.4 %
Shares of West Pharmaceutical Services stock traded up $44.21 on Thursday, reaching $330.65. The company had a trading volume of 1,983,070 shares, compared to its average volume of 558,379. The firm’s 50 day moving average price is $299.60 and its two-hundred day moving average price is $322.81. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. West Pharmaceutical Services has a 52-week low of $265.00 and a 52-week high of $413.70. The firm has a market cap of $23.99 billion, a PE ratio of 47.03, a PEG ratio of 10.21 and a beta of 1.01.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. During the same period in the previous year, the firm earned $2.11 EPS. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year. Sell-side analysts predict that West Pharmaceutical Services will post 6.42 earnings per share for the current fiscal year.
Insider Activity
About West Pharmaceutical Services
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
- Five stocks we like better than West Pharmaceutical Services
- Health Care Stocks Explained: Why You Might Want to Invest
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- About the Markup Calculator
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.